Article Per Year (5 Year)
p-Index From 2021 - 2026
5.871
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cardiology Heart Science Journal Narra J Jurnal Klinik dan Riset Kesehatan Deka in Medicine
Anjarwani, Setyasih
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 45 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 45 Documents
Search

 1   2   3   4   5 
The complex relationship between arterial carbon dioxide levels and acute heart failure: implications for prognosis and management Afifah, Yuri; Prasetya, Indra; Anjarwani, Setyasih; Pashira, Andranissa Amalia
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.2

Abstract

Acute Heart Failure (AHF) can affect carbon dioxide levels in the body by altering the balance between ventilation and carbon dioxide production, leading to either hypocapnia or hypercapnia. Arterial carbon dioxide (CO2) levels are essential for maintaining respiratory function and acid-base balance. However, the relationship between arterial CO2 levels and AHF remains complex and not fully understood. Diverse factors affect arterial CO2 levels in patients with AHF, including neurohormonal activation, respiratory compensation for hypoxemia, and changes in pulmonary perfusion. Hypocapnia, characterized by low arterial CO2 levels (PaCO2 < 35 mmHg), is commonly observed in AHF due to hyperventilation-driven respiratory alkalosis secondary to pulmonary congestion. It showed a strong connection with the survival rates of patients following a cardiac arrest. Nevertheless, elevated levels of carbon dioxide in the blood, known as hypercapnia, with a partial pressure of arterial carbon dioxide (PaCO2) exceeding 45 mmHg, can also arise in the later phases of acute heart failure (AHF), indicating fatigue in respiratory muscles or deterioration in pulmonary edema. Abnormal arterial CO2 levels have been associated with increased morbidity and mortality in AHF patients, serving as a valuable prognostic marker.  
Predictive value of PaCO2 on mortality in patients with acute heart failure Afifah, Yuri; Prasetya, Indra; Baskoro, Shalahuddin Suryo; Anjarwani, Setyasih
Heart Science Journal Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2025.006.01.9

Abstract

Background: Patients with AHF may experience fluctuations in carbon dioxide levels, resulting in either hypercapnia or hypocapnia. Recent research has highlighted the significance of the relationship between CO2 fluctuation and patient outcomes. Objective: The aim of this study was to explore the relationship between arterial carbon dioxide pressure (PaCO2) upon admission to the ICCU in patients with AHF. Methods: A single centre retrospective observational study was performed, the patient were enrolled from patient medical record between 2021 and 2023. Participants were divided into three groups based on PaCO2 levels. The study end point was length of hospitalization, mortality at ICCU and mortality in hospital. Statistical analysis used various tests to compare outcomes, with significance set at p<0.05, and ROC analysis evaluated mortality prediction. Result: The study included 150 patients: 97 with hypocapnia, 33 with normal PaCO2, and 19 with hypercapnia. In-hospital mortality was 37.5%, and 1-month mortality was 33.3% in the hypercapnia group. PaCO2 >45 mmHg was linked to higher in-hospital mortality (OR 6.900, p <0.001) and 30-day mortality (OR 5.600, p <0.001), PaCO2 <35 mmHg showing a protective association in ICCU and in-hospital mortality (OR 0.202, p<0.001) and 30-day mortality (OR 0.237, p<0.001). Length of stay was not significantly affected by either hypocapnia or hypercapnia. The ROC for predicting in-hospital mortality was 0.648 and for 30-day mortality was 0.626 in the PaCO2 >45 mmHg group. Conclusion: PaCO2 levels at ICCU admission predict mortality in AHF patients. Hypercapnia is associated with higher in-hospital and 30-day mortality, while hypocapnia appears protective.
Management of Decongestion in Acute Heart Failure: Time for a New Approach? Pramudyo, Miftah; Putra, Iwan Cahyo Santosa; Zulkarnain, Edrian; Danny, Siska Suridanda; Bagaswoto, Hendry Purnasidha; Anjarwani, Setyasih; Mazwar, Irmaliyas; Juzar, Dafsah Arifa; Pratama, Vireza; Habib, Faisal; Ispar, Akhtar Fajar Muzakkir Ali; Widyantoro, Bambang
Jurnal Kardiologi Indonesia Vol 43 No 2 (2022): Indonesian Journal of Cardiology: April - June 2022
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.1381

Abstract

As the primary cause of hospitalization in acute heart failure (AHF) patients, congestion was responsible for a higher risk of mortality, rehospitalization, and renal dysfunction in AHF patients. Although loop diuretic was routinely used as the mainstay of AHF therapy, it is still ineffective to obtain the euvolemic state in most hospitalized AHF patients. Therefore, a higher loop diuretic dose was often required to increase the decongestion effect. However, consequently, it can cause several detrimental complications, including renal dysfunction, neurohormonal activation, hyponatremia, hypokalaemia, and reduced blood pressure, which eventually result in poor prognosis. Hence, the new approach may be proposed to optimize decongestion in acute phase, including the use of arginine vasopressin V2 receptor antagonist – Tolvaptan. As an additive therapy to loop diuretic in AHF patients, it can be considered due to its several beneficial effects, including greater decongestion effect, lowered worsening renal function incidence, counteract neurohormonal activation, neutralized hyponatraemic state, no alteration of potassium metabolism, stabilize the blood pressure, and reduced requirement of a higher dose of loop diuretic to achieve an equal or even greater decongestion effect compared to a high dose of loop diuretic alone. Tolvaptan provided favourable outcomes in several specific populations and was considered safe with several mild adverse effects. Several guidelines across countries have approved the use of Tolvaptan in AHF patients with or without hyponatremia. The initial dose of Tolvaptan was 7.5 to 15 mg and can be titrated up to 30 mg. However, further studies were still required to determine the timing dose and optimal dose of Tolvaptan in general and elderly populations with AHF, respectively.This article has a related Erratum.
Management of Decongestion in Acute Heart Failure: Time for a New Approach? Pramudyo, Miftah; Putra, Iwan Cahyo Santosa; Zulkarnain, Edrian; Danny, Siska Suridanda; Danny, Hendry Purnasidha; Anjarwani, Setyasih; Mazwar, Irmaliyas; Juzar, Dafsah Arifa; Pratama, Vireza; Habib, Faisal; Ispar, Akhtar Fajar Muzakkir Ali; Widyantoro, Bambang
Jurnal Kardiologi Indonesia Vol 46 No 4 (2025): October - December, 2025
Publisher : The Indonesian Heart Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30701/ijc.2036

Abstract

In “Management of Decongestion in Acute Heart Failure: Time for a New Approach?” (Indonesian Journal of Cardiology, 43(2), 77-89. https://doi.org/10.30701/ijc.1381), there is an error noted. An error has been found in the PDF version of this article. The DOI printed in the PDF is incorrect. The correct DOI is https://doi.org/10.30701/ijc.1381. The error occurs only in the PDF; the DOI listed in the article metadata is already correct. The publisher apologizes for any inconvenience caused by this error.DOI of original article: https://doi.org/10.30701/ijc.1381
Acute pulmonary embolism following radiofrequency catheter ablation in a young asian female on hormonal contraceptive injection Triatmojo, Nicodemus; Rizal, Ardian; Wikananda, Adhika Prastya; Kurnianingsih, Novi; Anjarwani, Setyasih
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.17

Abstract

Background: Acute pulmonary embolism (APE) is an uncommon yet severe complication following radiofrequency catheter ablation (RFCA) for arrhythmic disorders, with reported incidences ranging from 0% to 1.7%. Hormonal contraceptive injections, specifically Depot Medroxyprogesterone Acetate, significantly increase the risk of venous thrombosis. Early identification of APE is challenging due to non-specific symptoms, but critical indicators include sudden shortness of breath, chest pain, and loss of consciousness. Timely and tailored treatment, including weight-based dose adjustments for fibrinolytic therapy in Asian patients, is crucial for optimal outcomes. Case Presentation: We present the case of a 23-year-old Asian female with no prior history of thromboembolic diseases, who was on Depot Medroxyprogesterone Acetate for contraception. She underwent an uncomplicated RFCA procedure for frequent premature ventricular contractions. Patient was immobilized for nine hours post-procedure, upon her first attempt to mobilize and walk to the bathroom, she suddenly experienced shortness of breath, chest pain, and a brief loss of consciousness. Her vital signs were unstable, with a blood pressure of 85/55 mmHg, heart rate of 133 bpm, respiratory rate of 32 breaths/minute, and oxygen saturation of 88%. Echocardiography revealed right ventricular dilatation and a positive McConnell sign. A CT pulmonary angiography confirmed a filling defect in the left pulmonary artery, leading to an APE diagnosis. Considering her Asian ethnicity and low BMI, the patient was successfully treated with a reduced dose of alteplase (50 mg) administered over two hours to minimize bleeding risk. Her vital signs stabilized during fibrinolytic therapy, with no hemorrhagic complications. Following three months of oral rivaroxaban treatment, a follow-up CT pulmonary angiography revealed complete resolution of the embolism. Conclusions: This case underscores that APE, though rare, is a serious complication of RFCA, especially when combined with prolonged immobilization and hormonal contraceptive use. The abrupt onset of symptoms, including shortness of breath and loss of consciousness upon initial mobilization, is a critical indicator of Acute PE. Early mobilization within 2-4 hours post-RFCA is indicated to minimize embolic risk. Individualized treatment strategies, such as weight-based fibrinolytic dosing, are essential for managing APE in specific patient populations to optimize efficacy and safety. Clinicians should exercise caution with patients using hormonal contraception undergoing procedures involving vascular puncture.
Co-Authors Adi, Andi Wahjono Afifah, Yuri AJI, BAYU Andria Priyana Aryanugraha, Teguh Ashari, Yordan Wicaksono Astiawati, Tri Atma Gunawan Bagaswoto, Hendry P. Bambang Widyantoro Baskoro, Shalahuddin Suryo Caesario, Fahreza Cholid Tri Tjahjono Danny, Hendry Purnasidha Danny, Siska S. Dewi U. Djafar, Dewi U. Djanggan Sargowo Emil Fathoni, Emil Endang, Jusup Faisal Habib Galih Prakosa, Ardani Habib, Faisal Hakim, Afdhalun Hakim, Dennis I. Hakim, Dennis Ievan Haryati, Lina Hendry Purnasidha Bagaswoto Ilhami, Yose R. Ilhami, Yose Ramda Indra Prasetya Iskandar Iskandar Ispar, Akhtar Fajar Muzakkir Ali Juzar, Dafsah A. Juzar, Dafsah Arifa Karolina, Wella Kurnianingsih, Novi Kurniawan, Dea Arie Lestari, Puspa Martini, Heny Mayangsari, Veny Mazwar, Irmaliyas Miftah Pramudyo Mohammad S. Rohman Mohammad Saifur Rohman Muzakkir, Akhtar F. Muzakkir, Akhtar Fajar Nahar Taufiq, Nahar Nugraha, Krishna Ari Nugraha, Tria Yudha Nugraha, Yudha Tria Nurudinulloh, Akhmad Isna Pashira, Andranissa Amalia Pratama, Vireza Pratiwi, Irma Kamelia Putra, Iwan Cahyo Santosa Putri, Valerinna Yogibuana Swastika R A, I Made Junior Raharjo, Fajar Rahimah, Anna Fuji Rizal, Ardian Rosyidi, Muhammad Azhar Ruspiono, Evit Sakti, Pradhika Perdana Saskia Dyah Handari Satrijo, Budi Setiawan, Dion Siska Suridanda Danny Sungkar, Safir Suprayoga, Imam Mi'raj Swastika Putri, Valerinna Yogibuana Triatmojo, Nicodemus Vori, Ira Widito, Sasmojo Wikananda, Adhika Prastya Wirawan, Hendy Yogibuana, Valerinna Yudha, Tria Zulkarnain, Edrian zunardi, Lutfi hafiz